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ABSTRACT The FK506-binding protein (FKBP12) is important in the immunosuppressant action of FK506 and rapamycin.
We have investigated Trp side chain dynamics in FKBP1 2, with and without a bound immunosuppressant, by measuring the
Trp time-resolved fluorescence anisotropy decay r(t). The r(t) for W59 in aqueous uncomplexed FKBP1 2 at 200C is well
described by a single exponential with a recovered initial anisotropy, ref, of 0.192 and an overall rotational correlation time
for the protein, 4p, of 4.7 ns; reff = 0.214 and p = 4.2 ns for the FKBP1 2/FK506 complex. Using an expression for the order
parameter squared, namely S2 = reff/rT, where rT is the vitrified steady-state excitation anisotropy, we recovered an S2 of 0.75
for W59 fluorescence in uncomplexed FKBP1 2 and s2 1 in the FKBP1 2/FK506 complex. Results obtained for the
FKBP12/rapamycin complex are similar to those found for the FKBP12/FK506 complex. Minimum perturbation mapping
simulations were performed on the free and complexed forms of FKBP1 2 and the results were generally in agreement with
the experimental data.
INTRODUCTION
The FK506-binding protein, FKBP12, is an important com-
ponent in the immunosuppressant action induced by the
drugs FK506 and rapamycin (Bierer et al., 1990; Clipstone
and Crabtree, 1992; Schreiber, 1992). Both drugs invoke
immunosuppression only after binding to FKBP12, and
each complex leads to a different response (Sigal and Du-
mont, 1992; Schreiber and Crabtree, 1992). The FKBP12/
FK506 complex binds and inactivates a Ca2+/calmodulin-
dependent protein phosphatase, calcineurin (Liu et al.,
1991), which ultimately leads to arrest at the GO-Gi cell-
cycle transition for the T cell through inhibition of the T-cell
receptor signal transduction pathway. The FKBP12/rapa-
mycin complex binds to a protein that is highly related to
products of the DRR/TOR gene (Brown et al., 1994), and
this leads to an inhibition of the interleukin-2 receptor
pathway, thus preventing T-cell proliferation at the G1-S
cell-cycle transition. Even though the above immunosup-
pressants inhibit the peptidyl-prolyl cis-trans isomerase
(PPIase) activity of FKBP12 (Siekierka et al., 1989; Hard-
ing et al., 1989), it has been shown that PPIase inhibition
does not account for the immunosuppressive action of the
drug (Sigal and Dumont, 1992; Schreiber and Crabtree,
1992).
Given the encouraging immunosuppressant properties of
FK506 relative to those of the less potent but traditionally
used immunosuppressant cyclosporin A (Thomson, 1989;
Starzl et al., 1990; Starzl, 1993), there has been and con-
tinues to be great interest in understanding the molecular
mechanisms underlying the biochemistry of FKBP12-es-
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pecially with regard to its interactions with immunosuppres-
sant drugs. X-ray derived crystal structures are available for
the FKBP12/FK506 complex (Van Duyne et al., 1991a), the
FKBP12/rapamycin complex (Van Duyne et al., 1991b), the
FKBP12/L-685,818 complex (Becker et al., 1993), the un-
complexed FKBP12 crystal structure (Wilson et al., 1995),
and the FKBP12/FK506/calcineurin complex (Griffith et
al., 1995); NMR-derived solution structures also exist for
uncomplexed FKBP12 (Michnick et al., 1991; Moore et al.,
1991). These data, however, fail to account for the possible
effect of protein dynamics in ligand recognition, and there is
reason to believe that such motions might contribute signif-
icantly to ligand binding (Yu, 1977; Munro et al., 1979;
Frauenfelder et al., 1991; Rasmussen et al., 1992). Changes
in FKBP12 dynamics upon ligand binding have been inves-
tigated by Cheng et al. in their 15N NMR relaxation mea-
surements of the protein's backbone (Cheng et al., 1993,
1994). They observed that the mainchain comprising resi-
dues 82-87, which forms a loop surrounding part of the
ligand-binding site, becomes rigidly fixed upon FK506
binding to FKBP12 (Cheng et al., 1994).
To our knowledge there has been little study of the role of
side chain dynamics on ligand binding. Yet, it seems ap-
parent that side chain dynamics often do play a substantial
role, and our lack of understanding may be the basis for the
difficulty of many current attempts at structure based drug
design (Verlinde and Dijkstra, 1995; Schevitz et al., 1995).
Indeed, we would argue that a priori side chain interactions
are principal determinants of the configuration of the bind-
ing site for many ligands. For example, a simulated drug-
docking calculation conducted by our group for FK506 and
rapamycin binding to FKBP12 suggests that these drugs
will not interact with the protein when the docking simula-
tion begins with the uncomplexed NMR solution structure;
the drug docks perfectly, though, when the x-ray derived
protein structure of complexed FKBP12 is employed (Pang
et al., 1994). We believe the disparity derives from our
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failure to properly consider side chain mobilities in the
docking simulation.
The solitary Trp residue in FKBP12, W59, has been
identified as essential for the interaction of FKBP12 with
FK506 (Moore et al., 1991), although it is not obvious why.
The fluorescence of this Trp residue changes upon drug
binding, and this change has been used to monitor ligand
binding (Marquis-Omer et al., 1991; Park et al., 1992) and
protein stability (Egan et al., 1993). However, there has
been little study of W59 dynamics despite the role its
mobility could play in drug interaction. In this paper, we are
concerned with the dynamics of W59. We have two objec-
tives: First, we want to measure W59 mobility by use of
time-dependent fluorescence anisotropy and to measure the
fluorescence lifetimes, realizing that the latter may also be
indicative of Trp side chain dynamics. Second, we are
simulating W59 dynamics in an attempt to rationalize the
fluorescence data. With regard to fluorescence lifetimes, for
example, the prevailing interpretation of heterogeneous life-
times invokes the existence of multiple Trp side chain
conformations, i.e., the so-called rotamer model (Hutnik
and Szabo, 1989; Rayner and Szabo, 1978), or alternatively
a distribution of conformational substates (Alcala et al.,
1987). Physical, or even theoretical evidence to corroborate
these inferences is seldom presented (Harris and Hudson,
1990). At a minimum, a demonstration that more than one
side chain conformation is feasible would be helpful. Fur-
thermore a demonstration of possible interconversion be-
tween conformational states on the fluorescence time scale
would also be valuable. To simulate Trp side chain dynam-
ics we use the minimum perturbation mapping technique
developed by Haydock (1993) from which an energy land-
scape for W59, as a function of its side chain XI, X2
dihedrals is calculated. In principle, molecular dynamics
calculations could provide such insights, but the calcula-
tions are complicated by the length of time such simulations
would have to run, i.e., into the nanosecond time frame.
However, if we assume that the dynamical motions of W59
are solely determined by its XI, X2 dihedral, then minimum
perturbation mapping allows us to consider the whole range
of phase space.
METHODS
Expression and Purification of human FKBP12
Our purification procedure for human FKBP12 generally follows that
described by Wiederrecht et al. (1992). Escherichia coli BL21 (DE3)
competent cells (Novagen, Madison, WI) were transformed by plasmid
pEThFKBP that was kindly provided by Dr. A. Marcy of Merck Research
Laboratories. The transformed cells were then grown for 24 h on Luria-
Bertani (LB) agar plates containing 100 ,ug/mL ampicillin at 37°C. This
was followed by overnight growth of single colonies in 25 mL flasks of LB
medium containing 100 ,ug/mL ampicillin at 37°C. One 25-mL culture
flask was then used to inoculate 1 L LB containing 100 ,ug/mL ampicillin
at 37°C in a shaker broth. When the culture optical density at 600 nm
reached 0.5-0.6 (typically 2 to 3 h after inoculation) FKBP12 expression
was induced by adding isopropyl i3-D-thioglucopyranoside (IPTG) into the
broth to a final concentration of 0.5 mM. The culture was then allowed to
grow for another 10-11 h. After harvesting by ultracentrifugation and
resuspension of the pellet twice in 20 mL 20-mM TRIS pH 7.4, the bacteria
were stored overnight at -70°C and later thawed at room temperature.
FKBP12 was released from the cell periplasm upon thawing and subse-
quently separated from unbroken cells and insoluble debris by ultracen-
trifugation. Thereafter, 1 niL 5% protamine sulfate was added to the
resulting supernatant and stirred for 30 min at 4°C. The suspension was
centrifuged and the resulting supernatant was concentrated to a volume of
9 to 10 mL, filtered and loaded onto a 175-mL Sephadex G-75 column
containing a running buffer of 20-mM sodium phosphate, 50-mM Na2SO4,
1-mM ethylenediaminetetra acetic acid (EDTA) and 0.5-mM phenylmeth-
ylsulfonyl fluoride (PMSF). Collected fractions of FKBP12 were identified
by SDS-PAGE, transferred to a 20 mM TRIS pH 8.0 buffer and concen-
trated to a volume of about 5 mL. The solution was then injected at 1
mLJmin through a 5-mL HiTrap Q anion exchange column (Pharmacia
Biotech, Uppsala, Sweden) that was equilibrated with 20-mM TRIS at pH
8.0. Purified FKBP12 came out in the void volume. The FKBP12 yield,
using an extinction coefficient of 9860 M- 1 cm-' at 280 nm, was typically
18-20 mgs per liter of LB medium. The FKBP12 sample was then dialyzed
extensively in 50-mM potassium phosphate buffer pH 7.0 and stored with
4-mM sodium azide at 4°C. We verified through SDS-PAGE and Coom-
assie blue staining that 1) FKBP12 was produced by the bacterial cells only
after IPTG induction, and 2) negligible amounts of FKBP12 were left
within the cell cytoplasm. e
The fidelity of FKBP12 expression was verified by a sequence analysis
of the first 39 amino terminus residues. The purity of the sample was also
checked via HPLC by applying a 5 to 40% acetonitrile gradient over 69
min on a C-18 column (Applied Biosystems) from which was observed a
single absorbance peak at 214 nm making up approximately 98% of the
total signal area. In addition, the purity of the HPLC processed protein was
verified using matrix-assisted laser desorption time of flight mass spec-
trometry (MALDI-TOF). HPLC fractions of FKBP12 were prepared for
mass spectrometry by mixing the protein with a photoactive matrix, 3,4-
dimethoxy-4-hydroxy-cinnamic acid and crystallizing the mixture on a
steel target. A Bruker Biflex MALDI-TOF instrument (Bruker Instrument,
Inc., Breman, Germany) was used in reflection mode to acquire the data. A
single dominant charged peak was observed at m/z = 11821.5. The mass
of this peak agreed well with 11819.5, the expected average molecular
weight of FKBP12, and was within the 0.1% experimental error of the
instrument. Finally, the protein PPIase activity was confirmed using an
assay developed by Harrison and Stein (1990). The recovered kca!KM for
our purified FKBP12, using the Suc-Ala-Leu-Pro-Phe-pNA peptide
(Bachem Bioscience, Inc., Philadelphia, PA) as a substrate, agreed closely
with the literature (Park et al., 1992).
Immunosuppressant drugs
Immunosuppressant drugs FK506, kindly provided by Fujisawa Pharma-
ceutical Co., Ltd. (Osaka, Japan), and rapamycin (Biomol Research Lab-
oratories, Plymouth Meeting, PA) were used without further purification.
The immunosuppressants were weighed out with 10-5 g precision on a
Mettler H51AR weigh balance and dissolved in high purity dimethyl
sulfoxide (DMSO) from Burdick and Jackson (Muskegon, WI).
Absorption spectrum
The absorption spectra of uncomplexed FKBP12 and FKBP12 complexed
with either FK506 or rapamycin were measured using a UV-VIS Cary
2200 spectrophotometer (Varian Techtron Pty, Ltd., Mulgrave, Australia).
Data were taken at 0.2-nm intervals with a spectral bandwidth of 0.5 nm,
a scan rate of 0.2 nm/s and a response time of 3 s. The spectral range
covered 260-310 nm.
Steady-state fluorescence
Steady-state fluorescence spectral measurements were performed on a
Perkin-Elmer MPF-66 fluorescence spectrophotometer (Perkin-Elmer,
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Norwalk, CT) using 300-nm excitation (5-nm monochromator bandpass).
The fluorescence emission was measured over the range 310-450 nm.
During measurements all samples were kept at a temperature of 20°C.
Whenever possible, the sample absorbance at 300nm was kept around 0.1.
This was not possible for the FKBP/rapamycin complex because of the
high extinction coefficient of rapamycin(E300n. = 12,500 M-1 cm' in
DMSO) in which case the fluorescence intensity was corrected for exci-
tation inner filter effects (Lakowicz, 1983).
Low temperature steady-state excitation anisotropy measurements were
performed on a Spex Flurolog spectrophotometer (SPEX Industries, Inc.,
Edison, NJ) equipped with a 0.22-m excitation monochromator and a
Pelletier cooled photomultiplier tube. The emission was observed through
an optical filter combination of UGI (Melles Griot, Irvine CA) and two
cut-on filters (WG345 and WG360) yielding half maximum transmittances
at 357 and 384 nm. This optical arrangement minimized tyrosine fluores-
cence contributions to the excitation anisotropy. Filters were used for
emission collection instead of the SPEX monochromator because of the
unacceptably high g factors (.3) associated with this monochromator;
with filters, g factors of approximately 1 were obtained. The excitation
range covered 270-310 nm in steps of1 nm with a 3-s integration time.
Only uncomplexed and FK506-complexed samples were considered, and
both were dissolved in 66% (redistilled) glycerol:buffer mixtures at protein
concentrations on the order of 100 to 200,uM.
Near-UV circular dichroism
Near-UV circular dichroism measurements of uncomplexed FKBP12 were
performed at 20°C using a Jasco J-710 spectropolarimeter (Jasco, Tokyo,
Japan). The sample was placed in a 0.5-cm pathlength cell at a concentra-
tion of 22,uM. The spectral range covered 250-320 nm using a 1.0-nm
bandwidth.
Time-resolved fluorescence intensity and
anisotropy decay
The Trp time-resolved fluorescence intensity and anisotropy decay of
uncomplexed and complexed FKBP12 at 20°C were measured using time-
resolved single-photon counting (O'Connor & Phillips, 1984). All samples
were excited at 300 nm using the frequency-doubled output of a Coherent
model 700 rhodamine dye laser that was pumped by the frequency-doubled
output of a Coherent Antares YAG laser (Coherent, Palo Alto, CA). The
fluorescence emission at 350 nm was observed through a 10-nm bandpass
optical filter. Anisotropy decay measurements were performed by acquir-
ing the time-dependent vertically and horizontally polarized fluorescence
intensity decays (1g1(t) and I,(t), respectively), when excited by vertically
polarized light, using a multi-channel plate detector. The instrument re-
sponse function was recorded using a scattering solution, and it yielded a
full width at half maximum of 50 ps; 3200-3600 channels were collected
at 4.4 ps/channel using the Nucleus PCA-II data acquisition card (Oxford
Instruments, Inc., Oak Ridge, TN). The protein concentrations for the
time-resolved measurements were 200 ,uM for uncomplexed FKBP12
measurements, 50 ttM for the FKBP12/FK506 complex measurements
(with a 1.5-times molar excess of FK506 added), and 20 ,uM for the
FKBP12/rapamycin complex measurements (with a 2.0-times molar excess
of rapamycin added).
Data were analyzed using the Globals Unlimited program (Beechem &
Gratton, 1988). The fluorescence intensity decay I(t) was analyzed as a
sum of decaying exponentials
N
I(t) = >ajexp(-t/Tj) (1)
i=-
with each ith term having lifetime Ti and amplitude ai. The fluorescence
anisotropy decays were analyzed by fitting 111(t) and I,(t) to the following
expressions
(2)
(3)
with the time-dependent anisotropy r(t) given by
r(t) = ro(S2 + (1 -S2)exp(-t/4W))exp(-t/4p)) (4)
or
r(t) =reoff exp(-t/op) (5)
where r. in Eq. 4 andrdff in Eq. 5 are the recovered initial anisotropies, S
is the order parameter, 4, is the rotational correlation time associated with
the Trp residue motion and 4p is the rotational correlation time of the
protein molecule as a whole. Unless noted, all parameter errors were
determined by the rigorous error analysis routine in the Globals Unlimited
software using a confidence limit of 67%.
Typically, satisfactory fits of r(t) to either Eqs. 4 or 5 are considered
plausible if the recovered initial anisotropy is either close to the measured
true initial anisotropy for free Trp (0.310 at 300-nm excitation), or if the
value can be rationalized by an independent measurement of the true initial
anisotropyrT of the system in question. For the case where Eq. 5 yields a
superior description forr(t) we purposely denoteddoff as an "effective"
initial anisotropy ifoff deviates significantly fromro. We can still reason
that ioff is physically derived fromrJ if in Eq. 4 we set r. = ro and take
46 << Op. As a result, Eq. 4 essentially reduces to Eq. 5, which is a single
exponential having a pre-exponential factor of roT s2 that we denote as an
effective initial anisotropydoff defined by
eff Te- = r.S20 (6)
Eq. 6 allows us to determine S2 from parameters recovered in a fit to Eq.
5 provided we have some independent means of measuring the true initial
anisotropy r:7. In our study, we determined rT for Trp fluorescence in the
protein by steady-state anisotropy measurements of the protein dissolved in
a glycerol-water glass at -46°C (Valeur and Weber, 1977).
Theoretical calculations
Minimum perturbation mappings of W59 were performed using the
CHARMM 22 executable code and specialized FORTRAN programs
kindly provided by Dr. C. Haydock (Brooks et al., 1983; Haydock, 1993).
Map calculations used the all-hydrogen CHARMM 22 parameter and
topology file (Momany and Rone, 1992). Because the simulations placed
FKBP12 in vacuum, ionizable residue charges were reduced by 80% and
the dielectric constant was made numerically equal to the distance in
Angstroms between interacting atoms to approximate solvent screening
effects (Sharp, 1993). Nonbonded interactions were switched off over the
range of 7.0 to 11.0 A. In this work, even though we refer to a residue set
to its crystallographic or NMR solution conformation, all FKBP12 struc-
tures in this study were conjugate gradient minimized for five steps to relax
any energetically unfavorable bond lengths and atom overlap (the final
structure generally differed by about 0.05 A RMS from the initial struc-
ture).
The map starts out by fixing the Trp side chain at a particular Xi, X2
point and setting all other residues to their crystallographic coordinates in
the case of FK506 or rapamycin-complexed FKBP (Van Duyne et al.,
1991a, b); for uncomplexed FKBP the coordinates of the 20 NMR solution
structures were used (Michnick et al., 1991). Throughout this paper XI is
defined by the bond connectivity N-CG-C,3-CY and X2 is defined by the
bond connectivity C,-C-3Cy,C82. Then, for each Trp dihedral point, resi-
dues nearby Trp were allowed to conformationally relax so as to achieve
energy minimization. The nearby residues included V24, Y26, F46, F48,
V55, 156, E60, V63, L74, I76, F99 and VIOI. The resulting energy V was
assigned as V = V(XI, X2). The minimization procedure, used at each Trp
dihedral point, was 40 steps by the steepest descent method, 280 steps by
the Powell method and, with SHAKE (van Gunsteren and Karplus, 1980)
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applied, 40 steps by the Powell method. This process is repeated in 5° or
10° steps over the whole angular space of XI and X2-
Interconversion rates and order parameters were calculated from the
maps according to previously discussed methods and are summarized as
follows (Haydock, 1993). Based on transition state theory, in a two
dimensional space, the interconversion rate kRp from reactant R to product
P is given by
(2i/3,)&Cl exp(-3,V(xf , X2))
R fRfR2 exp(- 3V(X1, X2))dxl dx2
where V (Xf, X2*) is the potential energy at the transition state region, ?)2 iS
the positive eigenvalue resulting from a diagonalization of V about the
transition state region (which is assumed to be quadratic), RI and R2 denote
the integration region defining the reactant state, and f3 = I/(kBT) where k.
is Boltzmann's constant and T is the absolute temperature. In this work, we
will consider the interconversion time from reactant R to product P, which
is equal to l/kRp.
The experimentally derived order parameter squared is customarily
defined to depend on the rotations of the fluorophore relative to the protein,
but not on the rotations of the transition dipole relative to the fluorophore.
We approximately decouple the dipole and fluorophore rotations by ex-
pressing the calculated order parameter squared S.2 as
P2(cos(5))S2
(8)
4v YT(Oa, 0a)Ym'(0e,fe)E(D )(D )
mm' m"f
where P2 is the second-order Legendre polynomial, 6 is the angle between
the absorption and emission transition dipoles, Y2' is the second-order
spherical harmonic, O6 and 4i are the polar and azimuthal angles of the
absorption (i = a) and emission (i = e) transition dipole in the fluorophore
frame, and (D(2) ,) is the ensemble average of the second-order rotation
matrix element describing the transformation from the fluorophore refer-
ence frame to a frame attached to the protein. Integers m, m' and m" range
from -2 to +2. The above approximation for S,2 fails when 6 is near the
magic angle giving P2(cos(S)) - 0. Eq. 8 is the same as that derived by
Haydock, except that his order parameter squared included the electronic
dipole rotation, which is approximately removed by the P2(cos(s)) factor
(Haydock, 1993).
If it is determined that the experimental anisotropy decay is best
described by a single exponential decay, then Sc2 determined by Eq. 8 can
be compared to the experimentally derived order parameter squared Se2 via
Eq. 6 through the relation Se = r This assumes that the fluorescence
originates from a single emission transition dipole. When the fluorescence
results from more than one emission transition dipole, then Sc2 can be given
by
= lrIfrTS(Sc T (9)
where N is the number of emission transition dipoles andf, is the fractional
intensity attributed to the ith emission transition dipole, which has a true
initial anisotropy value of rj,,. S2 is the order parameter squared derived
through Eq. 8 from the ith emission transition dipole. A derivation of Eq.
9 is given in Appendix A; however, the main assumptions inherent in Eq.
9 are that 1) a single absorption transition dipole is exclusively excited in
the system, and 2) the fluorescence intensity decay from each emission
transition dipole is the same, save for a scale factor determined by the
fractional intensityfi. Once r. is obtained the fractional intensitiesf, can be
determined for Eq. 9 by the equation.
N
T If=ro i.rii (10)
i=l1
given that we assume some reasonable values for 'T, which will be
discussed more in the Results section.
RESULTS
Absorption spectrum
The absorption spectrum of uncomplexed FKBP12 in 50
mM-potassium phosphate buffer at pH 7.0 (data not shown)
is typical of proteins bearing both Trp and Tyr residues
(Wetlaufer, 1962). Upon addition of FK506 to yield a 1:1
protein-drug complex (whose stoichiometry was verified by
observing W59 fluorescence quenching in a titration exper-
iment), the absorption spectrum changes markedly (FK506
itself displays a relatively low extinction, and a subtraction
of its absorption was implemented on the observed
FKBP12/FK506 complex absorption). Prominent features
of the FKBP12/FK506 complex absorption spectrum, rela-
tive to that of uncomplexed FKBP12, include a red shift of
about 2 nm and increased spectral structure in the 280 and
290 nm regions. Indeed, N-acetyl-tryptophan-amide also
displays the same qualitative absorption changes when it is
transferred from an aqueous environment to a 90% dioxane/
water mixture (data not shown), suggesting that the indole
moiety of W59 is subject to decreased polarity upon ligand
binding.
In the case of the FKBP12/rapamycin complex, a decom-
position of the rapamycin absorption spectrum from
FKBP12/rapamycin absorption spectrum could not satisfac-
torily yield an FKBP12 spectrum similar to the ones ob-
served for uncomplexed or FK506-complexed FKBP12. In
particular, the resulting decomposition tended to retain
prominent features of the rapamycin absorption spectrum
(data not shown), which include three peaks around 268 nm,
278 nm, and 292 nm attributed to the triene group of
rapamycin. The strong extinction of rapamycin (i.e., 44,700
M-1 cm-1 at 280 nm) compared to uncomplexed FKBP12
(9860 M-1 cm-' at 280 nm) is the likely reason for our
inability to recover the FKBP12 absorption.
Steady-state fluorescence measurements
The W59 fluorescence spectrum of uncomplexed FKBP12
at 200C, shown on Fig. 1 (solid line), displays an emission
maximum (Amax) at 330 nm. Qualitatively, the blue-shifted
fluorescence spectrum of FKBP12, relative to aqueous Trp,
indicates partial sequestration of the indole moiety from
water, but no quantitative significance can be attributed to
the term "partial sequestration." The water accessibility
calculated from the NMR structures of uncomplexed FKBP
yielded a range of 0 to 6 A2, which should be compared to
the value of 210 A2 for free indole dissolved in water.
Finally, the quantum yield of uncomplexed FKBP12, using
aqueous Trp as a reference, is 0.014, which is about 10% of
the value for free Trp in aqueous solvent (Demas and
Crosby, 1971).
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FIGURE 1 Fluorescence spectra, resulting from 300-nm excitation, of
uncomplexed FKBP12 (solid line), FKBP12 complexed with FK506
(dashed line), and FKBP12 complexed with rapamycin (dotted line), which
was corrected for the background fluorescence of aqueous rapamycin
shown in the inset. All spectra are shown as a function of emission
wavelength.
The dashed line curve of Fig. 1 shows the resulting
fluorescence spectra of the FKBP12/FK506 complex in a
1:1 stoichiometry that displays a Xma, at 335 nm and de-
creased intensity relative to uncomplexed FKBP12. FK506
displays a solubility in water of about 70 ,uM (derived from
the 620 M-1 cm-' extinction of FK506 in DMSO at 300
nm), however no fluorescence was observed for aqueous
FK506 when it was excited at 300 nm. As a result, the
dashed curve of Fig. 1 is the resulting fluorescence of W59.
Integrating over the emission spectrum shows that FK506
quenches the steady-state fluorescence of uncomplexed
FKBP12 by 28%. We took advantage of the quenching of
W59 fluorescence by FK506 to verify the 1:1 stoichiometry.
Qualitatively, all of our observations are in accord with
previous steady-state fluorescence measurements of W59
(Park et al., 1992; Marquis-Omer et al., 1991).
A fluorescence contaminant was observed for aqueous
rapamycin with 300-nm excitation and its spectrum is
shown in the inset of Fig. 1. We used the aqueous rapamy-
cin fluorescence spectrum (rapamycin had an apparent
aqueous solubility of about 27 ,uM) in the inset of Fig. 1 to
subtract the background fluorescence of the drug from the
fluorescence emission of the FKBP12/rapamycin complex.
In addition, the resulting FKBP12/rapamycin complex flu-
orescence intensity had to be corrected for excitation inner
filter effects because of the high extinction coefficient of
rapamycin at 300 nm according to the method described by
Lakowicz (1983). The 1: 1 FKBP12/rapamycin complex flu-
orescence spectrum is shown as the dotted line of Fig. 1.
Above 325 nm there is close agreement between this spec-
trum and that of the FKBP12/FK506 complex. Below 325
nm large Rayleigh scattering originating from the original
background subtraction spectrum prevented a satisfactory
spectrum of the FKBP12/rapamycin complex. Nevertheless,
rapamycin quenches the steady-state fluorescence of W59
in FKBP12 by about the same amount as FK506 given the
similarity between the two FKBP12 complexed spectrum.
Steady-state exciation anisotropy and near-UV CD
The absorption results of FKBP12 complexed with FK506
strongly suggest electronic interaction between W59 and
FK506. This raises questions regarding the value for rT to
be used for calculations which led us to measure the exci-
tation anisotropy profile of uncomplexed FKBP12 and
FKBP12 complexed with FK506 in a 66% glycerol:water
glass at -46°C. The fluorescence spectrum of uncomplexed
FKBP12 and the FKBP12/FK506 complex in 66% glycerol
at 20°C showed a 1-2 nm blue shift, relative to its aqueous
spectrum. In other words, neither the uncomplexed FKBP12
nor the FKBP12/FK506 complex in 66% glycerol shows a
substantially changed local electronic environment about
W59, relative to that seen for the fully aqueous protein.
Fig. 2 shows the resulting low temperature (-450C)
steady-state excitation anisotropy of uncomplexed FKBP12
(dashed line) and the FKBP12/FK506 complex (solid line).
The excitation anisotropy of uncomplexed FKBP12 shares
similar features to the excitation anisotropy of Trp in pro-
pylene glycol at -58°C (Valeur and Weber, 1977). The
main difference between uncomplexed FKBP12 and free
Trp is the decreased magnitude of the excitation anisotropy
of FKBP12 over the range 270-310 nm, relative to that of
free Trp in a similar glass. For instance, the value of the
uncomplexed FKBP12 anisotropy at 300 nm is 0.256,
whereas for Trp it is 0.310 (Valeur and Weber, 1977). The
observed difference in the low temperature anisotropy be-
tween free Trp and a single Trp protein or peptide has
already been reported by Lakowicz et al. (1983). In fact,
they recovered low temperature anisotropies at 300 nm in
the range of 0.255 to 0.269, which is relatively close to the
value we obtained for uncomplexed FKBP12. However, the
excitation anisotropy of FKBP12 complexed with FK506
(solid line of Fig. 2) shows a much different excitation
wavelength dependence than that observed for uncom-
plexed FKBP12. Of particular significance, is the decreased
anisotropy value of 0.200 for the FKBP12/FK506 complex
at 300 nm, relative to that of uncomplexed FKBP12.
0.35
v 0.30
o 0.25*_
0 0.20
r 0.15
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FIGURE 2 Excitation anisotropy of uncomplexed FKBP12 (dashed line)
and FKBP12 complexed with FK506 (solid line) in 66% glycerol at -45°C
as a function of excitation wavelength.
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The excitation anisotropy spectrum of uncomplexed
FKBP12 suggests that the aromatic residues closely circum-
scribing W59 may interact electronically to give a lower
anisotropy value than that for free Trp in vitrified solution.
To investigate this possibility we measured the near-UV CD
of uncomplexed aqueous FKBP12 at 20°C and the resulting
spectra (data not shown) show a distinct CD signal that
includes two peaks at 280 and 287 nm having molar ellip-
ticities of 25.7 and 42.8 deg cm2 dmol- 1, respectively. This
evidence is suggestive of aromatic residue interaction in
FKBP12, though it is not sufficient to conclude specific
aromatic residue interaction with W59.
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Time-resolved fluorescence intensity and
anisotropy decay
The W59 time-resolved fluorescence intensity decays of
both uncomplexed and drug complexed FKBP12 at 200C
were best described by four fluorescence lifetimes (fits of
the data to a distribution of lifetimes yielded unacceptably
high x). Table 1 shows the recovered values. For uncom-
plexed FKBP12, the lifetimes yield a fractional intensity
weighted average lifetime, (T), of 3.3 ns that increases to 4.1
ns in the FKBP12/FK506 complex. The long lifetime com-
ponent of both samples accounts for about 60% of the total
intensity and also shows the greatest change after FK506 is
bound to FKBP12-from 4.75 ns in uncomplexed FKBP12
to 5.43 ns in the complex. The magnitude of error in the
lifetime components, determined from several repeated life-
time measurements, is -5-7%.
The time-resolved fluorescence anisotropy decay of uncom-
plexed and FK506 complexed FKBP12 at 20°C was well
described by a single rotational correlation time; adding a
second rotational correlation time (i.e., Eq. 4) yielded essen-
tially no change in x2. Fig. 3 shows the W59 time-resolved
fluorescence anisotropy decay of uncomplexed FKBP12. Ta-
ble 2 displays the recovered parameters for the W59 time-
resolved anisotropy decay. The recovered overall rotational
correlation times p of 4.7 ns for uncomplexed FKBP12 and
4.2 ns in the FKBP12/FK506 complex closely agree with those
predicted by the Stokes-Einstein relation (4.65 ns) for a spher-
ical molecule of radius 16.5 A, the latter being the approximate
dimension of FKBP12 determined from NMR solution struc-
tures of uncomplexed FKBP12 (Michnick et al., 1991). For
uncomplexed FKBP12, the recovered initial anisotropy reff of
0.192 is significantly lower than the measured low temperature
anisotropy (0.256), excited at 300 nm. The FKBP12/FK506
complex yields a recovered initial anisotropy rgff of 0.214 that,
FIGURE 3 Calculated W59 fluorescence anisotropy decay of uncomplexed
FKBP12 at pH 7.0 and 20°C as a function of time. The top and bottom insets
show the residuals resulting from the data fit to the observed vertically and
horizontally polarized fluorescence of uncomplexed FKBP12.
to within an experimental error of 5%, overlaps its low tem-
perature anisotropy of 0.200 (error of 2%) at an excitation of
300 nm.
In the case of the FKBP12/rapamycin complex the fluores-
cence from rapamycin interferes with the measurement of the
time-resolved W59 fluorescence of FKBP12. Consequently,
we performed a background subtraction of the time-resolved
fluorescence anisotropy decay of the FKBP12/rapamycin com-
plex; that is, the vertically and horizontally polarized fluores-
cence emission decays of aqueous rapamycin were subtracted
from the corresponding time-resolved polarized fluorescence
emission of the FKBP12/rapamycin complex. Table 2 shows
that we can get a satisfactory fit from the analysis (X2 of 1.1
with background subtraction versus 1.95 with no subtraction).
More importantly the results are very similar to that of
FKBP12 complexed with FK506. In particular, increases in doff
and (T) are observed with respect to those of uncomplexed
FKBP12. Indeed, the roff for the FKBP12/rapamycin complex
is, to within experimental error, equal to that recovered for the
FKBP12/FK506 complex. The recovered overall rotational
correlation time of 4.9 ns also agrees closely with the previous
results from uncomplexed FKBP12 and the FKBP12/FK506
complex.
SIMULATIONS
Uncomplexed FKBP12
Before proceeding, we must describe the nomenclature we
employ to denote the putative configurational states which
TABLE I Fluorescence lifetime results: fluorescence amplitudes a, and lifetimes i,
Sample a1 Ta2 T2 a3 3 a4 4
FKBP12 0.09 4.75 0.08 1.95 0.26 0.29 0.57 0.10 1.2
FKBP12 + FK506 0.06 5.43 0.06 1.81 0.11 0.24 0.77 0.05 1.2
FKBP12 + Rapamycin* 0.10 5.24 0.14 2.25 0.12 0.44 0.64 0.07 1.1
*Analysis was done with background subtraction of rapamycin fluorescence.
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TABLE 2 Time-resolved fluorescence anisotropy decay results
Sample (T). 52 =
W59 FKBP12 0.192 4.7 3.3 1.2 0.256 0.75
W59 FKBP12 + FK506 0.214 4.2 4.1 1.2 0.200 1.0
W59 FKBP12 + Rapamycintt 0.218 4.9 3.7 1.1
*<off= initial anisotropy from time-resolved experiments. Errors are ± 5%.
Op= overall rotational correlation time in ns. Errors are ± 15%.
(T)= Average fluorescence lifetime in ns obtained through fractional intensity weighted lifetimes.
qX2= reduced chi-square for anisotropy fit.
II = steady-state anisotropy obtained at low temperature and high viscosity. Errors are ± 2%. **52 = order parameter squared defined by 52 = eoffli.
Errors are ± 5% by propagation of errors.
ftAnalysis was done with background subtraction of rapamycin fluorescence.
the Trp side chain can adopt. The XI axis is partitioned into
gauche-plus (g+) for 0° < XI < 120°, gauche-minus (g-)
for -120° < Xi < 00, and trans (t) for 120° < XI < 180°
and -180° < XI < -1200. The X2 axis is also partitioned
as perpendicular (p+) for 00 < X2 < 180° and antiperpen-
dicular (p-) for -180° < X2 < 0. Thus, an isomer lying in
one of six possible partition regions in XI, X2 space is
categorized by two letters, the first of which signifies the XI
region of occupation and the second the X2 region.
Minimum perturbation map calculations of W59 in un-
complexed FKBP12 were performed on the NMR solution
structure of uncomplexed FKBP12 deposited in the
Brookhaven Protein Data Bank (Michnick et al., 1991).
Even though two averaged NMR structures (PDB entries
lfks and lfkt) of uncomplexed FKBP12 were deposited, in
addition to the 20 NMR structures (PDB entry lfkr) from
which the averaged ones originate, our calculations concen-
o
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FIGURE 4 W59 minimum perturbation map of a)
the first FKBP12 NMR model, b) Ala mutant structure
of the first FKBP12 NMR model, c) the first FKBP12
NMR model with F48 and V63 isomerized to their
secondary isomeric conformations; L50A and E50A
mutations are also included, and d) FKBP12/FK506
complex with F48 and V63 isomerized to their second-
ary isomeric conformations; L5OA and E5OA muta-
tions are also included. The maps are displayed as
relative energy contour maps with the minimum (zero)
energy coordinate indicated by g-p+ for a), x for b),
tp+ for c), and g-p- for d). The energy is in kcal/mol
and the dashed contours indicate odd integer energy
values (1, 3, 5, .. .); the solid contours indicate even
integer energy values (2, 4, 6,.. .). Dotted contours
indicate energies greater than 15 kcal/mol.
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trated on the latter structural set. We chose to do this
because we did not want the conclusions drawn from our
simulations to depend on any averaging algorithms from
which the structures lfks and lfkt were derived; in partic-
ular, we believe confidence in our results will be enhanced
by considering structures that have a direct association with
the acquired data rather than those resulting from a post-
processing of the final data. For our calculations we con-
centrated on the first NMR model of lfkr. First we present
W59 map calculations that essentially portray W59 to be
surrounded by nearby residues, which themselves display
little conformational flexibility. These calculations are then
compared with W59 map calculations that incorporate sub-
stantial conformational flexibility for the nearby residues.
Fig. 4 a shows the W59 minimum perturbation map of
uncomplexed FKBP12, and it predicts that state g-p+ for
W59 has a Boltzmann-weighted probability of 0.99 at
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FIGURE 5 Stereo picture of region about W59 that includes nearby residues as defined in paper as well as C22 and M66 whose sulfur atom are
emphasized as orange balls: a) W59 conformation obtained from the NMR structural data (blue) and predicted by a minimum perturbation map of W59
(yellow) using the same NMR structural data; the NMR solution structure of F48 (green) and V63 (magenta) are also emphasized. b) W59 isomers g-p-
(yellow) and tp+ (blue) as predicted from a W59 minimum perturbation map in which F48 (green) and V63 (magenta) are isomerized to their secondary
isomeric conformations. The molecular graphics were done using the QUANTA program.
300K. However, this predicted W59 conformational mini-
mum is different from the conformation given by the NMR
solution structure, which is marked by x on Fig. 4 a. Fig. 5
a displays the discrepancy between the NMR solution struc-
ture of W59 in blue and the predicted W59 conformation
from the map calculations in yellow. If we define the
deviation of the predicted W59 minimum from the NMR
W59 solution structure as being the Pythagorean distance
between the two dihedral coordinates, we get a deviation of
560 for the case of the first NMR solution structure. A likely
cause for the deviation noted in Fig. 5 a may derive from an
inadequate solvent model. Another possible contribution to
the deviation may be the inherently low resolution of the
NMR structures. Nevertheless, the first NMR solution struc-
ture gives a relatively low deviation, in comparison with the
other NMR models (calculations not shown), thus bolster-
ing our confidence in using this structure as a basis for
comparison with the experimental fluorescence data, be-
cause, to a relative extent, the map calculation satisfies
structural constraints imposed by the NMR structural data.
The map calculations on the first NMR solution structure
presented various predictions about W59 conformational
heterogeneity and flexibility. For instance, in addition to the
predominantly single isomeric state g-p+ of the W59 map
in Fig. 4 a, another isomer, denoted by tp+, was predicted
with a low occupation probability of 0.01 at 300K. At this
temperature, isomerization from state tp+ to g-p+ would
require an interconversion time of 47 ns, whereas the re-
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verse direction had a interconversion time of 3 ,us. Such
long interconversion times, as compared to the average
fluorescence lifetime of FKBP12, suggests a rather inflex-
ible system on the nanosecond time scale. In addition, the
relatively high inflexibility of isomer g-p can be charac-
terized by its calculated order parameter squared S2 using
Eq. 8; for example, S2 1 would imply a rigid system,
whereas S2 0 would suggest a flexible system. However,
we must be careful as to how we calculate S2 because it is
dependent on what is assumed about the absorption and
emission transition dipoles. In particular, the order param-
eter squared depends on the orientation of the absorption
and emission transition dipole with respect to the chro-
mophore; for simplicity, in this initial analysis, we assume
that these transition dipoles lie in the plane of the indole
ring. The absorption and emission transition dipole orienta-
tion angles, Oa and Oe, respectively, relative to each other
determine the magnitude of the fluorescence anisotropy
decay. Information about these orientation angles can be
obtained by first knowing the true initial anisotropy ro of the
fluorophore and then applying the equation rT =
0.4P2(COs(Oa - Oe)) to solve for Oe, if Oa is known. In our
case, we measured an rT of 0.256 at 300 nm for uncom-
plexed FKBP12. Using the above relation, our value of rJ
would imply that the emission transition dipole is ±290
relative to the orientation of the 'La absorption transition
dipole (Yamamoto and Tanaka, 1972). Assuming this as the
origin for r: such a model would predict an S2 for state
g-p+ of essentially 0.89 for either emission transition di-
pole orientation.
Alternatively, an rT = 0.256 may be consequent to ultra-
fast intramolecular electronic processes involved in the con-
version of the 'La derived excited state to that derived from
the 'Lb transition dipole (Valeur and Weber, 1977). In
particular, 4r may result from fluorescence emission polar-
ized along the 'La or 'Lb transition dipole directions assum-
ing that the 'La dipole was exclusively excited at 300 nm.
This would lead to ro being given by the expression of Eq.
10; more explicitly, J? = fA(0.4) + fB(-0.2) wherefA and
fB are the fractional intensities arising from fluorescence
emission polarized along the 'La and 'Lb directions, respec-
tively. The factors 0.4 and -0.2 are the expected true
anisotropy values for fluorescence emission resulting from
the 'La and 'Lb directions, respectively, given that the 'La
transition dipole was excited. Thus, adopting 0.256 as 4? for
W59 and incorporating electronic internal conversion as the
origin for its value, fluorescence emission from uncom-
plexed FKBP12 would then result from both 'La and 'Lb
states with fractional intensity weights of 0.76 and 0.24,
respectively, at 300-nm excitation. This scenario, using Eq.
9, would yield an S2 of 0.89 for state g-p+.
Even though recent experimental evidence has shown
that Trp likely attains the theoretically maximum initial
anisotropy of 0.4, this value decreases quickly, within 2 ps,
via electronic internal conversion to approximately the 0.31
value obtained by Valuer and Weber (Ruggiero et al., 1990;
imental setup of 4.4 ps/channel and a full width at half
maximum of 50 ps, it may only be relevant to consider rT
measured for FKBP12 in a highly vitrified environment.
However, as noted by Bajzer et al., (1995) fluorescence
lifetimes lower than the channel width may be obtained
depending on the method used for discretization of the
instrument response function. At present, our analysis uses
the commonly implemented linear approximation (McKin-
non et al., 1977). In conclusion, whether we consider the
origin of or as being the result of electronic internal con-
version or a ±29° orientation of the emission transition
dipole relative to the 'La state, we obtain a high S2 for the
dominant g-p+ state.
Such high values of S2 implies a relatively immobilized
Trp side chain. In principle, the Trp side chain could exhibit
increased mobility if residues nearby were allowed to
isomerize away from Trp i.e., "collective" motions of
nearby side chains could allow the Trp side chain to have
several conformations. To get an idea of the full range of
W59 conformational flexibility we have simulated side
chain dynamics of residues near W59 by mutating them to
alanine (Ala). Physically, the mutated structure portrays,
relative to Trp, an average conformation in which thermal
agitation induces large XI dihedral rotations of a neighbor
residue. We refer to this structure as the Ala mutant struc-
ture and its resulting map as the W59 Ala mutant map. We
emphasize that the advantage of the W59 Ala mutant map is
the ease with which we can approximate the mobility of
residues neighboring the Trp side chain (reduced degrees of
freedom and less atom-to-atom interactions to consider).
The map serves as a starting point to explore the maximal
range of Trp flexibility. Such a map may not portray reality
with respect to a buried residue like W59. However, it at
least points the way toward suggesting alternative regions of
conformational space which Trp may occupy in addition to
its conformation described by the NMR solution data.
We show in Fig. 4 b that many Trp isomers are energet-
ically plausible for W59 in the Ala mutant structure with the
most probable Boltzmann-weighted isomer labeled as x. If
this map portrayed reality it would require a theoretical
demonstration that the real residues nearby W59 can
isomerize to conformations other than that given by the first
NMR solution structure. However, minimum perturbation
maps of nearby residues F99 and 156 showed that they
cannot occupy isomeric states sufficiently different from
those given by the NMR solution structure. In particular, the
maps of F99 and 156 showed that these residues would have
to overcome energy barriers greater than 10 kcallmol to
occupy very improbable isomeric conformations. Accord-
ingly, we were reconciled always to include both residues in
any further W59 map calculations. One consequence was
that the inclusion of F99 or I56 into the Ala mutant structure
(with their conformations given by the NMR solution struc-
ture) caused an elimination of the W59 isomers labeled z in
Fig. 4 b. This prompted us to consider W59 isomers other
than those labeled as z in Fig. 4 b. Consequently, our
Valeur and Weber, 1977). Thus, with respect to our exper-
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proximal to residues F48 and V63. As before, we would
only consider this region of conformational space as plau-
sible for W59 if it could be shown that F48 and V63 could
isomerize to conformations other than that given by their
NMR solution structure. As it turns out, energetically fa-
vorable isomers of F48 at XI = 170° and X2 = 90° was
predicted from an F48 minimum perturbation map of an Ala
mutant structure that included F46, W59, and F99 in their
NMR solution coordinates and also included an additional
Ala mutation of L5OA. We denote such isomers, which are
energetically favorable yet different from their given NMR
solution conformation, as secondary isomers. A secondary
isomer was also predicted for V63 at XI = 850 from its map
of an Ala mutant structure that included F46, W59, and F99
in their NMR solution coordinates. The secondary isomers
for F48 and V63 were plausible since they were only
separated from their NMR solution coordinates (the NMR
solution coordinates for F48 is Xi = 720 and X2 = 108° and
for V63 its XI = - 1670) by energy barriers on the order of
5.5-7.5 kcallmol. Thus, conformational flexibility of F48
and V63 suggested an alternative FKBP12 structure em-
ploying the secondary isomers of F48 and V63, which, as it
turns out, allowed for increased W59 flexibility.
This increased W59 flexibility was verified by a W59
map, Fig. 4 c, of the first NMR solution structure which
contained only two mutations, L5OA and E60A, and two
isomerizations of the nearby residues F48 and V63 to their
secondary isomeric conformations. The L5OA and E60A
mutations model the average flexibility of L50 and E60
about their XI dihedral so as to allow the isomerization of
F48 to its secondary isomer. To first order, these mutations
are plausible by the fact that L50 and E60 are relatively
nonbulky residues on the protein surface. One of the pre-
dictions of this map is the existence of, at most, two iso-
meric conformations for W59. Both conformations are dis-
played in Fig. 5 b. One isomer, g-p-, that has a 0.07
occupation probability at 300K and is colored yellow in Fig.
5 b, is close to g-p+ observed in the W59 map of Fig. 4 a.
The other, tp+, is colored blue in Fig. 5 b and it is attainable
from g-p- in an interconversion time of 3 ns; the reverse
interconversion time is 42 ns. With or without electronic
internal conversion, the S2 of these isomers range from 0.89
to 0.94. We can also calculate the combined order parameter
squared of both isomeric states. In particular, with no elec-
tronic internal conversion and an emission transition dipole
angle of -100, we obtain a combined S2 of 0.79. If we apply
electronic internal conversion, then the combined S2 be-
comes 0.74.
Complexed FKBP12
Even though crystallographic structures were provided for
complexed FKBP12 (for the case of the FKBP12/rapamycin
complex, residues 190 and V98 had two possible conforma-
tions listed as structure A or B in PDB file lfkb; we used
was assigning appropriate parameters to the immunosup-
pressants FK506 and rapamycin. As mentioned by Fischer
et al. (1993) and Orozco et al. (1993), care must be taken
when assigning the force field parameters to the proline
residues of peptides that can be isomerized by FKBP12. In
particular, standard parameters do not accurately model the
proline residue when it experiences large deviations from
the cis or trans states. This caveat is probably relevant to the
immunosuppressants, because both drugs contain a pipe-
colinyl ring that can be viewed as a proline analog in its
transition state between cis-trans isomerization (Albers et
al., 1990).
Given our uncertainty in the parameters of the whole drug
we opted for a conservative approach. That is, we generated
CHARMM parameters for the drugs using the QUANTA
program (Molecular Simulations, Inc., Burlington, MA). In
the parameter generation a total charge of zero was
smoothed over all drug atoms. Then in the minimum per-
turbation maps of complexed FKBP12 all drug atoms were
fixed. A more rigorous study would allow the drug atoms to
adjust position, provided that justifiable parameters are
known. We are currently working on the parameter assign-
ments for FK506 so that such a study can be conducted in
the future. Even though our present approach may be con-
sidered a first order approximation, it should be noted that
NMR relaxation measurements of FK506 bound to FKBP12
indicates that the drug macrocycle backbone is relatively
immobile on the picosecond time scale (Lepre et al., 1993).
Thus, there is at least some experimental basis for our
modeling of FK506.
In our simulation, because the drug is bound "on top" of
W59 and is fixed during minimization, only a single dom-
inant state can result from the W59 map. This raises the
question whether there is any value in a W59 map using a
model in which the drug is fixed. To answer this question
we did a control W59 map in which all of the neighboring
residues of the FKBP12/FK506 complex were mutated to
Ala. The resulting map (not shown) verifies the possible
existence of multiple isomeric states for W59 though not as
many as in the W59 Ala map of Fig. 4 b. Thus, if flexibility
is possible for the nearby residues in complexed FKBP12,
then W59 might also demonstrate some flexibility in the
FKBP12/FK506 complex.
However, as we have demonstrated in the uncomplexed
case, the Ala mutant structure is not the correct model to use
when trying to portray FKBP12 motional flexibility of
residues nearby W59. Rather only the isomerizations of F48
and V63 to their secondary isomers could be justified.
Applying these isomerizations as well as the L5OA and
E60A mutations to the protein in the FKBP12/FK506 com-
plex yields the W59 map of Fig. 4 d. The map clearly
displays less flexibility for W59 than the corresponding map
in Fig. 4 c of uncomplexed FKBP12. In particular, only a
single minimum, state g-p-, is observed for W59. This
minimum is close to the observed (measured) dihedral co-
ordinates, labeled x in Fig. 4 d, of W59 from the crystallo-
structure A), the difficulty we faced in this part of the study
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For our calculations of S2 we use the experimentally
determined r, of 0.200 obtained from the low temperature-
high viscosity measurements of the steady-state fluores-
cence anisotropy of the FKBP12/FK506 complex. With no
electronic internal conversion, state g-p- gives an S2 of
0.88 or 0.92 for Oe = -5° and Oe = -75°, respectively.
With electronic internal conversion, an S2 of 0.90 is calcu-
lated where the 'La absorption transition dipole contributes
approximately 0.66 of the fractional intensity. A map sim-
ilar to that of Fig. 4 d was recovered for the W59 map of the
FKBP12/rapamycin complex.
DISCUSSION
Proteins containing a single Trp residue display heteroge-
neous fluorescence intensity decays requiring a description
in terms of two or more fluorescence lifetimes (Beechem
and Brand, 1985). A variety of quenching mechanisms
apparently influence the nonradiative decay of excited-state
Trp. These mechanisms include charge transfer, resonance
energy transfer, proton transfer, and intersystem crossing
(Shizuka et al., 1988; Janes et al., 1987; Saito et al., 1984).
With the exception of resonance energy and electron trans-
fer, the deactivation mechanisms involve collisional inter-
action between the indole moiety and the quenching resi-
due. Two views rationalizing the observed heterogeneity in
the fluorescence intensity decay have emerged over the
years. The first view involves a "rotamer" model and pur-
ports that each lifetime component, which results from a fit
of the intensity decay to a finite number of exponentially
decaying terms, is due to a particular Trp isomer (Hutnik
and Szabo, 1989; Rayner and Szabo, 1978). From this
model, different lifetime values are due to the indole moiety
being in collisional contact with different moieties having
differing quenching efficiencies. The second rationalization
for fluorescence lifetime heterogeneity proposes the exis-
tence of conformational substates (Alcala et al., 1987;
Frauenfelder et al., 1988). This model holds that the pro-
tein's energy landscape is multidimensional, and, as a result,
a continuous distribution of Trp fluorescence lifetimes
arises from both a multitude of Trp isomers and different
rotational isomers of nearby quenching residues.
For the study of Trp fluorescence described here, the
principal issue is that all FKBP12 samples displayed a
complex heterogeneity in their W59 fluorescence intensity
decays as evident in the four lifetime components needed to
describe the experimental data. The fact that uncomplexed
FKBP12 shows a low quantum yield of 0.014, which is
about 10% of that found for free Trp in aqueous solution
(Demas and Crosby, 1971), clearly indicates substantial
quenching of W59 fluorescence. Yet, despite the extensive
quenching evident in the reduced quantum yield, long life-
time components (i.e., where T> 4.0 ns) persist indicating
the complexity of the quenching processes. The identities of
the latter are unclear. We assume that elements in the
protein matrix are primarily responsible and the possibility
of static versus dynamic quenching may also need to be
considered. However, the term "static quenching" as it may
be applied here within the commonly used lexicon is par-
ticularly unsatisfying. It becomes little more than a catch all
phrase to describe but not explain the results. The truth is we
do not know the basis for the recovered lifetimes yet the
pattern found in this work, namely low quantum yield and
a set of long T values is very common (Sedarous and
Prendergast, unpublished results). To the extent that we can
trust the recovery of parameters then the results must be
considered as "real." If so, then our usual explanations fail
precisely because we cannot identify the quenching mech-
anisms. Examination of the molecular environs of W59 and
of the near-UV CD spectrum for the protein suggests the
possibility of some ground-state electronic interaction but
these are not quantifiable. We also do not fully understand
what the consequences of such interactions would be on the
excited state decay although in general we would guess an
inevitable reduction in quantum yield and shortening of the
fluorescence lifetime. Beyond this consideration, examina-
tion of the residues immediately surrounding W59 shows no
obvious collisional quenching groups such as charged moi-
eties or sulfur containing residues (Steiner and Kirby, 1969;
Harris and Hudson, 1990).
Upon complexation the fluorescence quantum is reduced
further to '-0.01 and the fluorescence emission red shifts
(Park et al., 1992). This spectral shift to the red and the
fluorescence quenching by drug binding are interesting re-
sults. Calculations show that drug-bound protein has a water
accessibility for W59 of zero. Yet, commonly held views
would predict "moderate" water accessibility given the W59
fluorescence maximum of 335 nm. As for the quenching, in
both drug complexes with FKBP12 only the pipecolinyl
ring directly interacts with the indole moiety, as shown in
Fig. 6. Beyond this structural coincidence between the two
drugs there is no obvious explanation for the observed
quenching upon drug binding.
Another result of drug complexation is the increase of (T),
which agrees qualitatively with that observed for the
FK520-FKBP12 complex (Marquis-Omer et al., 1991).
However, the (T) of 2.1 ns obtained for uncomplexed
FKBP12 by Marquis-Omer et al. (1991) was a least a
nanosecond shorter than ours. The origin of this difference
is not obvious. However, in their study, FKBP12 was ex-
cited at 292 nm and the fluorescence signal measured may
have been contaminated by tyrosine emission. Nevertheless,
the increase in (T) contrasts obviously with the ligand-
induced decrease in quantum yield. A possible explanation
for this discrepancy may reside in a change in the radiative
lifetime of Trp after the ligand is bound. This change is
plausible considering that Trp may display a wide range of
radiative lifetimes in a variety of proteins (Szabo and Faer-
man, 1992). However, it is not obvious how to derive a
system's radiative decay rate when its decay is multiexpo-
nential, as the case is with FKBP12; our caution in this
matter is discussed in Appendix B.
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FIGURE 6 Stereo picture of W59 (green) and the FK506 (yellow) and rapamycin (red) drugs resulting from a superposition of the x-ray derived crystal
crystal structures of the FKBP12/FK506 and FKBP12/rapamycin complex. Hydrogen atoms were added on by the CHARMM program and the molecular
graphics were done using the QUANTA program.
Despite the difficulty we have in identifying the interac-
tions responsible for quenching, it is desirable to probe the
possible existence of multiple conformations for the Trp
side chain, i.e., the likelihood of credible "rotamers." Our
simulations of FKBP12 show that two W59 isoforms can be
rationalized in the case of uncomplexed FKBP12 and only
one in the case of the complexed FKBP12 (Fig. 4, c and d).
Thus, from both experimental and theoretical approaches
the Trp rotamer model as a source for the lifetime hetero-
geneity does not seem practicable if collisional mechanisms
are the primary mechanism of quenching. Plausible isomer-
izations of W59 and combinations of isomerizations of
nearby residues like V63, F48, V55 and VIOl (V55 and
VIOl were also shown to exhibit secondary isomers from
our simulations, data not shown) may coexist and could give
rise to a multitude of lifetimes were it not for the fact that all
residues nearby W59 are very weak quenchers, if they
quench at all. In general, these paradoxical changes in
quantum yield and fluorescence lifetimes, the manifest het-
erogeneity in fluorescence intensity decays and the absence
of obvious structural basis for these fluorescence properties
suggests that we may have paid insufficient attention to
quenching mechanisms that are not collisional, i.e., those
operating through space (Bajzer and Prendergast, 1993).
Finally, what must be realized is that it really does not
matter whether we interpret the heterogeneity of lifetimes in
terms of discrete exponentials or distributions. The use of
four exponentials terms is a consequence of the fitting
procedure and the results are fully reproducible, but the
physical meaning of the recovered parameters is clearly
problematic. Three exponential terms do not fit well; five
may be marginally better than four. The key issue is the
complexity of the decay and the apparent inadequacy of any
single model, rotamer-based or distribution of states, to
simply interpret the results.
Given the previous conclusions of the limited conforma-
tional states W59 can occupy, what can be concluded of the
motions of W59 and its relevance toward drug binding? In
this respect, our study presents two major implications
vis-'a-vis W59 motion that we now discuss.
Traditionally, a double exponential decay (Eq. 4) is used
to describe Trp motion if there is reason to believe the
motions implied actually exist. In the case of uncomplexed
FKBP12, the x2 of a double exponential fit is essentially
equivalent to a single exponential fit (Eq. 5) and, thus, the
latter is the preferred fit. The single exponential portrayal of
r(t) for W59 in uncomplexed FKBP12 suggests that the Trp
residue is rigidly "fixed", i.e., the experimentally derived S2
should be 1.0. This would clearly be the case if we could fit
r(t) to a single exponential with Plff fixed either to the rOT of
free Trp or that determined for W59 in uncomplexed
FKBP12 by our low temperature steady-state anisotropy
measurements. However, in either case the resulting fits
yielded an inferior x2 (>3).
This leads to an alternative explanation for the relatively
low r/ff = 0.192 value of W59 for uncomplexed FKBP12;
that is, it results from a double exponential decay represen-
tation of r(t) in which r. of Eq. 4 is the r?O value of 0.256,
and
,
<< p holds such that Eq. 4 reduces to the single
exponential expression of Eq. 5 where roff = roT S2. In other
words, if we were to freeze the sample and measure its
time-resolved anisotropy decay, the motion of W59 should
be slowed down such that an initial anisotropy of 0.256
would be recovered. Indeed, at 20°C, we can fit the anisot-
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ropy decay to Eq. 4 with r. fixed to 0.256 and get a 4w of
9 ps, 4p of 4.8 ns and an S2 of 0.74. However, such a fit
would yield an error on 4w on the order of 100% because its
X2 is equivalent to that of a single exponential decay fit.
Nevertheless, we can still adopt the single exponential fit by
appealing to a fast W59 depolarization that yields an 52 of
0.75 for uncomplexed FKBP12 using s2 = eoff/rT.
A similar line of argument rationalizing the use of a
single exponential decay for describing the anisotropy de-
cay of drug-complexed FKBP12 also applies. In particular,
the 0.200 value of rT and the recovered off of 0.214 for W59
in the FKBP12/FK506 complex, are equal within experi-
mental error, which implies an absence of W59 side chain
motion, giving s2 1.0 for W59 in the FKBP12/FK506
complex. With respect to rapamycin effects, because 1)
close similarity between the steady-state fluorescence emis-
sion spectrum of the FKBP12/rapamycin complex and that
of the FKBP12/FK506 complex exists, and 2) similar
changes in the recovered doff and (T) of both complexes
relative to that obtained for uncomplexed FKBP12 exist, we
believe that our results suggest an52 1 for W59 in the
FKBP12/rapamycin complex. Thus, the first major impli-
cation of this study is that the side chain dynamics of W59
may be an important factor in the ligand binding of immu-
nosuppressants FK506 and rapamycin to FKBP12.
Given the previous experimental facts, the SC2 calculated
from the W59 map of uncomplexed FKBP12 agrees with
the experimental s2 only if we assume that residues near
W59, namely F48 and V63, can readjust to their secondary
isomers. In particular, an Sc2 of - 0.74-0.78 resulted when
we combined states tp+ and g-p- in the map of Fig. 4 c,
which agrees closely with the experimentally recovered 52
of 0.75. Combining states tp+ and g-p- assumes that the
interconversion time between the two states is short com-
pared with the average fluorescence lifetime. Because of the
relatively large interconversion times between the two states
(3 ns and 47 ns) one would expect that a discernible 4w
value should be observed from the fluorescence anisotropy
decay of W59. This discrepancy may have its origin in the
way we modeled solvent effects on the map. Yet, use of a
more appropriate solvent model could completely change
our calculated S2, because the latter is derived from a
Boltzmann-weighted average as described in Eq. 8. Finally,
our calculations show the S2 of the combined states tp+ and
g-p- for uncomplexed FKBP12 increases from - 0.74 to
- 0.90 after FK506 is bound. Experimentally we see a
similar increase in S2 from the uncomplexed value of 0.75
to the complexed value of - 1.0. Overall, the simulations
are in qualitative accord with experiments in that the order
parameter of W59 increases after drug binding. Thus, the
second major implication of our study is that we can ratio-
nalize the observed fluorescence anisotropy decay of W59
through molecular simulations to give us a first order insight
into the mechanisms of W59 motion.
Considering that the drugs effectively increase the pack-
ing density directly above the indole ring in the FKBP12-
tal and theoretical results are physically consistent with the
implication that such a sequestering by the drugs would
restrain the mobility of W59. In addition, the calculated
average B-factor (B) of all heavy atoms for W59 supports
this notion for decreased W59 mobility in the protein-drug
complexes. (B) for W59 heavy atoms is 14.9 for uncom-
plexed FKBP12 (private communication, Dr. B. McKeever,
Merck Research Laboratories, Rahway, NJ) but is only 7.6
in the FKBP12/FK506 complex (Van Duyne et al., 1991a).
Even though the uncomplexed and FK506-complexed struc-
tures were derived from different crystal symmetry forms,
their (B) for all protein heavy atoms are relatively similar
with 14.9 for the uncomplexed structure and 13.7 for the
FK506-complexed structure. The x-ray data for both crystal
structures were acquired at similar temperatures. Such sim-
ilarity suggests that our comparison of (B) for W59 heavy
atoms is plausible.
Although our results agree qualitatively with changes of
(B) for W59, there is a major difference in the recovered
overall protein rotational correlation times determined by
fluorescence and NMR. The NMR relaxation measurements
yielded a Tm, which corresponds to p of Eq. 4, of 9.2 ns for
uncomplexed FKBP12 and 9.0 ns for the FKBP12/FK506
complex (Cheng et al., 1993, 1994). These values are almost
a factor of two greater than our p values of 4.7 ns for
uncomplexed FKBP12 and 4.2 ns for the FKBP12/FK506
complex. The NMR and fluorescence measurements were
both done in a 50-mM potassium phosphate buffer compo-
sition and at pH 7.0. Whereas our measurements were
performed at 20°C and the NMR relaxation measurements
were done at 30°C, this difference is not sufficient to
account for the observed differences in (AP. Discrepancies
between the NMR relaxation Tm and the time-resolved flu-
orescence anisotropy 4p have been observed in other studies
investigating the side chain dynamics of Trp and Tyr resi-
dues (Kemple et al., 1994; Palmer et al., 1993) and there are
as yet no convincing explanations.
Our results suggests the need for future studies with
respect to W59 side chain dynamics. The simulations sug-
gest that the origin of W59 motion is predominantly along
XI, if one assumes that the W59 anisotropy decay is deter-
mined primarily by its side chain dihedral motions rather
than by "breathing" motions of the peptide backbone or
electronic effects. The model predicts ways of testing for
these motions. In particular, site-directed mutagenesis of
F48 or V63 may influence the observed anisotropy decay of
W59. Further analysis also suggests that VIOl may be
interesting for mutagenesis studies, because it may steri-
cally hinder W59 and so may determine the barrier height
between states tp+ and g-p- of Fig. 4 c. In addition, our
study suggests a way to improve drug association with
FKBP12. Assuming that, from the crystal structure of the
FKBP12/drug complex, the W59 isomer g-p- of Fig. 4 c is
preferred over tp+ for drug association, improved drug
interaction may be affected by site directed mutagenesis of
residues determining the conformational freedom of W59 as
drug complex (Van Duyne et al., 199 la, b), our experimen-
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APPENDIX A
On the order parameter of a fluorescent system
having multiple emission transition dipoles
Fluorescence anisotropy decay data are fit to II(t) and I1(t) of Eqs. 2 and
3 and not directly to r(t). What follows is a derivation of Eq. 9 by
considering I11(t) although a similar derivation can also be applied to 11(t).
Assuming that fluorescence emission from a fluorophore originates
from N emission transition dipoles labeled by i after a single absorption
dipole is excited, I11(t) can be decomposed as
APPENDIX B
On the radiative decay of a multi-exponential
decaying system
The following discussion is derived from Prof. Gregorio Weber's lecture
notes. Let us consider a heterogeneous population of fluorophores each of
which decays as a single exponential. The ith fluorophore has a lifetime Tj
with a quantum yield qi defined by
kri
qi' knj + knri (17)
where kj is the radiative decay rate and knri is the nonradiative decay rate
of the ith species. Let us assume, for simplicity, that kri = kr. In other
words, all species have the same radiative decay rate. Furthermore, let ni
denote the concentration of ith molecular species excited. Then the frac-
tional intensity weighted average lifetime, (Ti, is given by
(T)= ET7niqi niqi
i
(18)
Because Ti = qilkr Eq. 18 becomes
where 1ll(t) is the vertically polarized fluorescence emission resulting from
the ith emission transition dipole; it is understood throughout this appendix
that all summations range from 1 to N.
Equation 11 can then be rewritten as
(12)
where li(t) and ri(t) are the fluorescence intensity and anisotropy decay
associated with the ith emission transition dipole. Assuming that each l(t)
differs from each other by a fractional intensity factorf associated with the
ith emission transition dipole, Eq. 12 then reduces to
kr(T)= In q2/Iniq
With the average quantum yield (q) defined by
(q)= Eniqi Ini
i
we redefine qi as
qi = (q) + 6qi
Using Eq. 21 it follows from Eq. 20 that
Enj5qj = 0
Because we are only considering one species of fluorophores with many
possible emission transition dipoles we can represent r,(t) as
ri(t) = rtjS2 exp( - t/lp) (14)
Applying Eqs. 21 and 22 to Eq. 19 gives
kr(T) = (q) + Enibq2/(q)
where it is assumed that the system has an overall rotational correlation
time of 4p and that the rotational correlation time of the fluorophore on the
macromolecule, 40, satisfies 4P << p so that the double exponential
representation of r(t) (Eq. 4) reduces to a single exponential (Eq. 5). This
gives rise to a pre-exponential factor similar to that discussed for reff of Eq.
6; that is, rli is the true initial anisotropy resulting from the ith emission
transition dipole and S2 is the order parameter squared due to fast nuclear
motion of the fluorophore. Substituting Eq. 14 into Eq. 13 gives
I11(t) = (1/3)1(t) (1 + 2reff exp(
-t1p)) (15)
The second term on the right hand side of Eq. 23 is always positive and it
follows that
(q) . kr(T) (24)
where the equality of Eq. 24 holds for a system that decays as a single
exponential; otherwise the inequality holds. (q) and (T) can be obtained
experimentally so that we can calculate the experimentally recovered
radiative decay rate keXP given by
k1exP =(q)-(T)
Thus Eq. 24 can be recast as
(kexp) > (kr)-'
from which S,2 is then given by Eq. 9 and can be compared with the
experimentally derived S2 of Eq. 6 provided we solve forf using Eq. 10.
(26)
Which states to us a warning: if you have a multiexponential decay then
your experimentally recovered radiative lifetime, using Eq. 25, may be
larger than the true radiative lifetime.
I (t)= I(t) (1 1)
(19)
(20)
(13)
(21)
(22)
(23)
where
rO = AOisi (16)
(25)
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III(t) = (113)1:I'(t) (I + 2ri(t))
III(t) = (113)I(t) (I + 21firi(t))
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